US · CODX
Co-Diagnostics, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Salt Lake City, UT 84109
- Website
- codiagnostics.com
Price · as of 2024-12-31
$1.55
Market cap 12.3M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.92 | +1,894.84% |
| Intrinsic Value(DCF) | $8.51 | +449.03% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $40.47 | +2,510.97% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $71.10 | $0.00 | $0.00 | ||
| 2018 | $36.00 | $73.02 | $0.00 | $0.00 | $0.00 |
| 2019 | $386.70 | $214.62 | $18,371.22 | $0.00 | $0.00 |
| 2020 | $418.20 | $5,674.37 | $48,023,322.59 | $10.45 | $52,596.27 |
| 2021 | $156.90 | $105.74 | $1,691.67 | $10.50 | $48.21 |
| 2022 | $85.80 | $86.20 | $33.14 | $1.38 | $24.44 |
| 2023 | $34.50 | $246.37 | $4.92 | $0.00 | $82.34 |
| 2024 | $16.80 | $30.92 | $2.02 | $0.00 | $40.47 |
AI valuation
Our deep-learning model estimates Co-Diagnostics, Inc.'s (CODX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.92
- Current price
- $1.55
- AI upside
- +1,894.84%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.51
+449.03% upside
Graham-Dodd
—
— upside
Graham Formula
$40.47
+2,510.97% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CODX | Co-Diagnostics, Inc. | $1.55 | 12.3M | +1,895% | +449% | — | +2,511% | -13.54 | 9.38 | 130.17 | -12.45 | -406.20 | 18.07 | 74.48% | -1023.75% | -961.37% | -53.65% | -140.21% | -47.25% | 0.04 | — | 4.41 | 4.08 | 0.02 | 333.00% | -4253.00% | 2754.00% | -5.87% | -3.99 | -104.61% | 0.00% | 0.00% | 0.00% | -12.03 | -16.12 | 123.12 | 29.30 |
| ADGM | Adagio Medical Holdings, … | $1.00 | 15.38M | +1,418% | -58% | — | +543% | -0.21 | 0.81 | 59.89 | -0.19 | — | -15.73 | -620.07% | -23226.77% | -19986.25% | 133.87% | 157.35% | -271.53% | 0.82 | 56.70 | 3.27 | 2.66 | 0.07 | -2716.00% | -1033.00% | 1971.00% | -193.09% | -3.79 | 78.34% | 0.00% | 0.00% | 256.59% | -0.19 | -0.38 | 43.83 | -5.52 |
| AEMD | Aethlon Medical, Inc. | $4.51 | 11.72M | — | — | — | — | -0.31 | 0.80 | — | 0.06 | -0.40 | 0.80 | 0.00% | — | — | -245.88% | -1215.78% | -171.58% | 0.13 | -924.06 | 3.13 | 2.90 | 0.37 | 7654.00% | — | -2635.00% | -185.54% | -4.03 | -995.06% | 0.00% | 0.00% | 8.49% | 0.08 | 0.10 | — | -34.37 |
| ALUR | Allurion Technologies Inc… | $1.70 | 13.16M | +10,605% | -43% | — | +20,584% | -0.21 | -0.07 | 0.17 | -1.26 | — | -0.07 | 66.97% | -156.33% | -81.43% | 35.22% | 82.22% | -50.03% | -0.49 | -22.17 | 1.44 | 1.19 | -1.02 | -7987.00% | -3994.00% | -3457.00% | -785.83% | -2.24 | 70.29% | 0.00% | 0.00% | 0.00% | -0.56 | -0.65 | 0.87 | -13.22 |
| DWTX | Dogwood Therapeutics, Inc… | $5.56 | 10.63M | — | — | — | — | -0.55 | 0.11 | — | -0.61 | -0.71 | -0.51 | 0.00% | — | — | -36.28% | -37.33% | -25.08% | 0.24 | -132.63 | 5.21 | 4.67 | -0.06 | 7759.00% | — | 8049.00% | -129.59% | -2.77 | -26.84% | 0.00% | 0.00% | 0.01% | -0.62 | -0.86 | — | -1.22 |
| NVNO | enVVeno Medical Corporati… | $0.68 | 13.71M | — | — | — | — | -0.07 | 0.04 | — | 1.91 | — | 0.04 | 0.00% | — | — | -49.39% | -3781.90% | -46.63% | 0.03 | — | 20.88 | 20.60 | 0.03 | -3351.00% | — | -1067.00% | -1122.35% | -8.04 | -2678.57% | 0.00% | 0.00% | 0.00% | 1.70 | 2.41 | — | -5.04 |
| PRPH | ProPhase Labs, Inc. | $0.30 | 12.38M | +7,780% | +464% | — | +68,378% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
| SINT | Sintx Technologies, Inc. | $3.47 | 9.57M | +16,195% | -62% | — | +17,893% | -0.22 | 0.63 | 1.98 | -0.30 | — | 0.64 | 34.91% | -1127.37% | -884.75% | -174.07% | -193.62% | -88.98% | 1.03 | -484.38 | 2.41 | 1.91 | -0.04 | -2178.00% | -5257.00% | -3628.00% | -378.55% | -4.36 | -128.63% | 0.00% | 0.00% | 40.16% | -0.21 | -0.31 | 2.32 | -46.07 |
| TNON | Tenon Medical, Inc. | $1.18 | 10.47M | +15,506% | +155,780% | — | — | -0.12 | 0.26 | 0.48 | 0.35 | — | 0.26 | 52.21% | -420.08% | -417.24% | -405.19% | -38777.46% | -168.93% | 0.07 | -404.88 | 4.39 | 3.96 | 0.47 | -8360.00% | 1192.00% | -1977.00% | -637.69% | -5.29 | -28349.30% | 0.00% | 0.00% | 350.78% | 0.33 | 0.45 | -1.38 | -13.04 |
| VVOS | Vivos Therapeutics, Inc. | $2.43 | 14.31M | +734% | +4,578% | — | — | -1.66 | 2.33 | 1.23 | -1.31 | — | 3.91 | 60.00% | -74.32% | -74.09% | -266.25% | -562.91% | -85.62% | 0.19 | — | 1.50 | 1.34 | 0.45 | -8007.00% | 891.00% | 400.00% | -71.58% | -2.55 | -668.13% | 0.00% | 0.00% | 27.53% | -1.23 | -1.04 | 0.92 | -9.26 |
| XAIR | Beyond Air, Inc. | $1.88 | 9.82M | +3,062% | -19% | — | — | -0.27 | 0.95 | 3.47 | -0.42 | — | 1.04 | -44.89% | -1202.08% | -1258.43% | -250.98% | -332.73% | -111.42% | 0.86 | -14.75 | 3.20 | 1.56 | -0.17 | -6210.00% | 21967.00% | -2859.00% | -342.82% | -7.64 | -329.47% | 0.00% | 0.00% | 0.00% | -0.40 | -0.40 | 4.76 | -17.17 |
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
- CEO
- Dwight H. Egan
- Employees
- 132
- Beta
- 1.15
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.51 ÷ $1.55) − 1 = +449.03% (DCF, example).